Horizon Therapeutics Scores $15 Million

Horizon Therapeutics Inc., a Palo Alto, Calif.-based drug developer, has raised $15 million in Series B funding. Scale Venture Partners (f.k.a. BA Venture Partners) led the deal, and was joined by fellow return backers Sutter Hill Ventures and Pequot Ventures. The company had raised a $6 million Series A round in late 2005 at a post-money valuation of approximately $17 million. Horizon's initial candidate is designed to provide pain relief while reducing stomach acidity during the peak time of risk for NSAID-induced ulceration. www.horizontherapeutics.com